Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19

Cited by (1,002)

Items 501–600 of 1,002

1. Generative artificial intelligence performs rudimentary structural biology modeling
   Ille, Alexander M., Markosian, Christopher, Burley, Stephen K., Mathews, Michael B., Pasqualini, Renata, Arap, Wadih · 2024 · Scientific Reports
2. 3-chymotrypsin-like protease in SARS-CoV-2
   Kenana Al Adem, Juliana C. Ferreira, Adrian J. Villanueva, Samar Fadl, Farah El-Sadaany, I. Masmoudi, Yugmee Gidiya, Tariro Gurudza, Thyago Hermylly Santana Cardoso, Nitin K. Saksena et al. · 2024 · Bioscience Reports
3. The roles of macrophages and monocytes in COVID-19 Severe Respiratory Syndrome
   Jun Li, Rui Shan, H. I. Miller, Alexander V. Filatov, Maria G. Byazrova, Lu Yang, Chaohong Liu · 2025 · Cell Insight
4. Virological and clinical rebounds of COVID-19 soon after nirmatrelvir/ritonavir discontinuation
   Guido Antonelli, Daniele Focosi, Ombretta Turriziani, Marco Tuccori, Rossella Brandi, Silvia Fillo, Camilla Ajassa, Florigio Romano Lista, Claudio Maria Mastroianni · 2022 · Clinical Microbiology and Infection
5. 4′-Fluorouridine Is a Broad-Spectrum Orally Available First-Line Antiviral That May Improve Pandemic Preparedness
   Carolin M. Lieber, Richard Karl Plemper · 2022 · DNA and Cell Biology
6. Early Access to Oral Antivirals in High-Risk Outpatients: Good Weapons to Fight COVID-19
   Giuseppe Bruno, Massimo Giotta, Serena Perelli, Giuseppina De Vita, Nicola Bartolomeo, Giovanni Battista Buccoliero · 2022 · Viruses
7. Plasma Apolipoprotein Concentrations Are Highly Altered in Severe Intensive Care Unit COVID-19 Patients: Preliminary Results from the LIPICOR Cohort Study
   Floran Bègue, Kévin Chemello, Bryan Veeren, Brice Lortat‐Jacob, Alexy Tran‐Dinh, Nathalie Zappella, Aurélie Snauwaert, Tiphaine Robert, Philippe Rondeau, Marie Lagrange-Xélot et al. · 2023 · International Journal of Molecular Sciences
8. Myocarditis: causes, mechanisms, and evolving therapies
   Tin Soe Kyaw, Grant Raymond Drummond, Alex Bobik, Karlheinz Peter · 2023 · Expert Opinion on Therapeutic Targets
9. COVID-19 in Adult Patients with Hematological Malignancies—Lessons Learned after Three Years of Pandemic
   Iwona Hus, Agnieszka Szymczyk, Joanna Mańko, Joanna Ewa Drozd-Sokolowska · 2023 · Biology
10. Integrated Covalent Drug Design Workflow Using Site Identification by Ligand Competitive Saturation
    Yu, Wenbo, Weber, David J., MacKerell, Alexander D. · 2023 · Journal of Chemical Theory and Computation
11. Effectiveness of oral antiviral agents on long‐term cardiovascular risk in nonhospitalized patients with COVID‐19: A multicenter matched cohort study
    Tinghui Liu, Min‐Hsiang Chuang, Jheng‐Yan Wu, Po‐Yu Huang, Ya‐Wen Tsai, Wan‐Hsuan Hsu, Chih‐Cheng Lai · 2023 · Journal of Medical Virology
12. Safety Profile and Clinical and Virological Outcomes of Nirmatrelvir-Ritonavir Treatment in Patients With Advanced Chronic Kidney Disease and Coronavirus Disease 2019
    Gordon Chun‐Kau Chan, Grace Chung-Yan Lui, Candy Ngai Sze Wong, Sindy S. T. Yip, Timothy Chun Man Li, Catherine S. K. Cheung, Ryan Kin Ho Sze, Cheuk‐Chun Szeto, Kai Ming Chow · 2023 · Clinical Infectious Diseases
13. An Overview on Anti-COVID-19 Drug Achievements and Challenges Ahead
    Mehdi Valipour, Hamid Irannejad, Hossein Keyvani · 2023 · ACS Pharmacology & Translational Science
14. Efficacy of Nirmatrelvir-Ritonavir versus Azvudine for COVID-19 Treatment in Tibet: A Retrospective Study
    Xiang yu Zhao, Yuan Cheng, Meng Zhang, Bianba Qianda, Baima Zhouma, Yangzhen Bianba, Yao Zheng, Shuo Zhang, Huiying Zhao · 2023 · Infection and Drug Resistance
15. Paxlovid as a potential treatment for long COVID
    Matthew William McCarthy · 2023 · Expert Opinion on Pharmacotherapy
16. Reversible and irreversible inhibitors of coronavirus Nsp15 endoribonuclease
    Jerry Chen, Rabih Abou Farraj, Daniel Limonta, Seyed Amirhossein Tabatabaei Dakhili, Evan M. Kerek, Ashim Bhattacharya, Filip M Reformat, Ola M. Mabrouk, Benjamin Brigant, Tom A. Pfeifer et al. · 2023 · Journal of Biological Chemistry
17. Clinical experience of treatment of immunocompromised individuals with persistent SARS-CoV-2 infection based on drug resistance mutations determined by genomic analysis: a descriptive study
    Haruka Shimazu, Daiki Wada, Shuhei Maruyama, Akira Inoue, Masami Kashihara, Tomoyuki Yoshihara, Fukuki Saito, Kazuhisa Yoshiya, Yasushi Nakamori, Yasuyuki Kuwagata · 2023 · BMC Infectious Diseases
18. Small-molecule anti-COVID-19 drugs and a focus on China’s homegrown mindeudesivir (VV116)
    Qiuyu Cao, Yi Ding, Yu Xu, Mian Li, Ruizhi Zheng, Zhujun Cao, Weiqing Wang, Yufang Bi, Guang Ning, Yiping Xu et al. · 2023 · Frontiers of Medicine
19. Ecofriendly bioanalytical validated RP-HPLC method for simultaneous determination of COVID-19 co-prescribed drugs employing quality by design and green chemistry
    Sohair mohamed aboelghar, Maha Abdel Monem Hegazy, Hebatallah A. Wagdy · 2024 · Microchemical Journal
20. Temporal changes in SARS-CoV-2 clearance kinetics and the optimal design of antiviral pharmacodynamic studies: an individual patient data meta-analysis of a randomised, controlled, adaptive platform study (PLATCOV)
    Phrutsamon Wongnak, William HK Schilling, Podjanee Jittamala, Simon Boyd, Viravarn Luvira, Tanaya Siripoon, Thundon Ngamprasertchai, Elizabeth M. Batty, Shivani Singh, Jindarat Kouhathong et al. · 2024 · The Lancet Infectious Diseases
21. Fecal microbiota transplantation alleviates mild‐moderate COVID‐19 associated diarrhoea and depression symptoms: A prospective study of a randomized, double‐blind clinical trial
    Xia Jiang, Xian Gao, Jiaqi Ding, Bo Pang, Yongbin Pei, Zifeng Zhao, Ning Zhao, Zibin Wang, Chengyang Chen, Da Gao et al. · 2024 · Journal of Medical Virology
22. Increased levels of circulating cell-free DNA in COVID-19 patients with respiratory failure
    Akihiko Tanaka, Katsuki Wakayama, Yosuke Fukuda, Shin Ohta, Tetsuya Homma, Koichi Ando, Yuji Nishihara, Ryuichi Nakano, Jing Zhao, Yuki Suzuki et al. · 2024 · Scientific Reports
23. Camostat Mesylate Versus Lopinavir/Ritonavir in Hospitalized Patients With COVID-19—Results From a Randomized, Controlled, Open Label, Platform Trial (ACOVACT)
    Mario Karolyi, Erich Pawelka, Sara Omid, Franz König, Victoria Kauer, Benedikt Rumpf, Wolfgang Hoepler, Ayşe Kuran, Hermann Laferl, Tamara Seitz et al. · 2022 · Frontiers in Pharmacology
24. Real-life data on monoclonal antibodies and antiviral drugs in Italian inborn errors of immunity patients during COVID-19 pandemic
    Giulia Garzi, Francesco Cinetto, Davide Firinu, Giulia Di Napoli, Gianluca Lagnese, Alessandra Punziano, Patrick Bez, Bianca Laura Cinicola, Giulia Anna Maria Luigia Costanzo, Riccardo Scarpa et al. · 2022 · Frontiers in Immunology
25. Managing nirmatrelvir/ritonavir during COVID-19: pharmacists’ experiences from the Perak state of Malaysia
    Chee Tao Chang, Su Yin Ong, Xin-Jie Lim, Lan-Sim Chew, PHILIP RAJAN DEVESAHAYAM · 2022 · Journal of Pharmaceutical Policy and Practice
26. Nirmatrelvir plus ritonavir in COVID-19: a profile of its use
    Hannah A. Blair · 2022 · Drugs & Therapy Perspectives
27. Coronavirus disease 2019 rebounds following nirmatrelvir/ritonavir treatment
    Chih‐Cheng Lai, Po‐Ren Hsueh · 2022 · Journal of Medical Virology
28. Effectiveness of Oral Nirmatrelvir/Ritonavir vs. Intravenous Three-Day Remdesivir in Preventing Progression to Severe COVID-19: A Single-Center, Prospective, Comparative, Real-Life Study
    Dimitrios Basoulis, Aristeidis Tsakanikas, Aikaterini Gkoufa, Aikaterini Bitsani, Georgios Karamanakos, Elpida Mastrogianni, Vasiliki Georgakopoulou, Sotiria Makrodimitri, Pantazis-Michail Voutsinas, Panagiota Lamprou et al. · 2023 · Viruses
29. Anti–SARS-CoV-2 Pharmacotherapies Among Nonhospitalized US Veterans, January 2022 to January 2023
    Lei Yan, Elani Streja, Yuli Li, Nallakkandi Rajeevan, Mazhgan Rowneki, Kristin Berry, Denise M. Hynes, Francesca E. Cunningham, Grant D. Huang, Mihaela Aslan et al. · 2023 · JAMA Network Open
30. Nirmatrelvir/ritonavir use in pregnant women with SARS-CoV-2 Omicron infection: a target trial emulation
    Carlos King Ho Wong, Kristy T. K. Lau, Matthew Shing Hin Chung, Ivan Chi Ho Au, Ka Wang Cheung, Eric H. Y. Lau, Yasmin Daoud, Benjamin John Cowling, Gabriel Matthew Leung · 2023 · Nature Medicine
31. Comparative effectiveness of Paxlovid versus sotrovimab and molnupiravir for preventing severe COVID-19 outcomes in non-hospitalised patients: observational cohort study using the OpenSAFELY platform
    Bang Zheng, John Tazare, Linda Nab, Amir Mehrkar, Brian MacKenna, Ben M. Goldacre, Ian Douglas, Laurie A. Tomlinson · 2023 · medRxiv
32. Community-acquired bacterial coinfections and COVID-19
    Michael John Patton, Amit Gaggar, Matthew Might, Nathaniel B. Erdmann, Carlos Javier Orihuela, Kevin S. Harrod · 2023 · Physiological Reviews
33. Fixing the Achilles Heel of Pfizer’s Paxlovid for COVID-19 Treatment
    Lennart Brewitz, Christopher John Schofield · 2024 · Journal of Medicinal Chemistry
34. Early treatment to prevent progression of SARS-CoV-2 infection
    Myron S. Cohen · 2022 · The Lancet Respiratory Medicine
35. Risk Factors for Slow Viral Decline in COVID-19 Patients during the 2022 Omicron Wave
    Xin Li, Anthony Raymond Tam, Wing-Ming Chu, Wan-Mui Chan, Jonathan Daniel Ip, Allen Wing‐Ho Chu, Syed Muhammad Abdullah, Cyril Chik‐Yan Yip, Kwok‐Hung Chan, Samson S. Y. Wong et al. · 2022 · Viruses
36. The effect of nirmatrelvir‐ritonavir on viral clearance and length of hospital stay in patients infected with SARS‐CoV‐2 omicron variants
    Yu Wang, Danyang Zhao, Xubo Chen, Xinbing Liu, Wenying Xiao, Liuliu Feng · 2023 · Influenza and Other Respiratory Viruses
37. The Impact of Nirmatrelvir-Ritonavir in Reducing Hospitalizations Among High-Risk Patients With SARS-CoV-2 During the Omicron Predominant Era
    Mohanad M. Al‐Obaidi, Ahmet B. Gungor, Sangeetha Murugapandian, Bijin Thajudeen, Iyad S. M. Mansour, Ryan C. Wong, Bekir Tanrıöver, Tirdad T. Zangeneh · 2023 · The American Journal of Medicine
38. A case report of a prolonged decrease in tacrolimus clearance due to co-administration of nirmatrelvir/ritonavir in a lung transplant recipient receiving itraconazole prophylaxis
    Ayumi Tsuzawa, Y. Katada, Keisuke Umemura, Mitsuhiro Sugimoto, Asami Nishikawa, Yuki Sato, Yuko Yoshida, Noriaki Kitada, Atsushi Yonezawa, Daisuke Nakajima et al. · 2023 · Journal of Pharmaceutical Health Care and Sciences
39. Evaluation of the Inhibition Potency of Nirmatrelvir against Main Protease Mutants of SARS-CoV-2 Variants
    Haihai Jiang, Yanru Zhou, Xiaofang Zou, Xiaohui Hu, Jie Wang, Pei Zeng, Wenwen Li, Xiangyi Zeng, Jin Zhang, Jian Li · 2023 · Biochemistry
40. Physiologically-Based Pharmacokinetic Modeling of PAXLOVID™ with First-Order Absorption Kinetics
    Kazuko Sagawa, Jian Lin, Rohit Jaini, Li Di · 2023 · Pharmaceutical Research
41. Social Determinants of Health and COVID-19
    Giselle S Mosnaim, Michelle Carrasquel, Anna R. Wolfson, Jonny Peter, David Michael Lang, Melinda McNeal Rathkopf · 2023 · The Journal of Allergy and Clinical Immunology In Practice
42. Effectiveness and Adverse Events of Nirmatrelvir/Ritonavir Versus Molnupiravir for COVID-19 in Outpatient Setting: Multicenter Prospective Observational Study
    Jin Ju Park, Hyunji Kim, Yong Kyun Kim, Seung Soon Lee, Eunju Jung, Jin Seo Lee, Jacob Lee · 2023 · Journal of Korean Medical Science
43. Real-world effectiveness of nirmatrelvir-ritonavir versus azvudine in hospitalized patients with COVID-19 during the omicron wave in Beijing: a multicenter retrospective cohort study
    Han Xiao-bo, Darui Gao, Chenglong Li, Xin Yuan, Junchang Cui, Weiguo Zhao, Fei Xie, Kaifei Wang, Yuhong Liu, Guoxin Muo et al. · 2024 · BMC Infectious Diseases
44. Improved fluorescence‐based assay for rapid screening and evaluation of SARS‐CoV‐2 main protease inhibitors
    Rui Zhang, Haohao Yan, Jiahao Zhou, Gangan Yan, Xiaoping Liu, Chao Shang, Yunyu Chen · 2024 · Journal of Medical Virology
45. COVID-19 Rebound After VV116 vs Nirmatrelvir-Ritonavir Treatment
    Zhitao Yang, Yu Xu, Ruizhi Zheng, Lei Ye, Gang Lv, Zhujun Cao, Rulai Han, Mian Li, Yuanyue Zhu, Qiuyu Cao et al. · 2024 · JAMA Network Open
46. Long COVID as a disease of accelerated biological aging: An opportunity to translate geroscience interventions
    Areez Shafqat, Mary Clare Masters, Utkarsh Tripathi, Tamar Tchkonia, James L. Kirkland, Shahrukh Khurshid Hashmi · 2024 · Ageing Research Reviews
47. Nebulized inhalation of plasma-activated water in the treatment of progressive moderate COVID-19 patients with antiviral treatment failure: a randomized controlled pilot trial
    Heng Zhao, Wanting Meng, Xing Lv, Jing Li, Zhigui Cai, Xingxing Guo, Zifeng Wang, Li Guo, Mingzhe Rong, Cong Shen et al. · 2024 · BMC Infectious Diseases
48. De Novo Discovery of a Noncovalent Cell-Penetrating Bicyclic Peptide Inhibitor Targeting SARS-CoV-2 Main Protease
    Yahong Tan, Jinyue Yang, Min Wang, Qi Peng, Yongqi Li, Lifeng Fu, Mengmeng Zhang, Jiang Wu, Guanya Yang, Christopher J. Hipolito et al. · 2024 · Journal of Medicinal Chemistry
49. Adverse Audio-Vestibular Effects of Drugs and Vaccines Used in the Treatment and Prevention of COVID-19: A Review
    Magdalena Beata Skarzynska, Monika Matusiak, Piotr Henryk Skarzynski · 2022 · Audiology Research
50. COVID-19 and Adult Acute Leukemia: Our Knowledge in Progress
    Franziska Modemann, Susanne Ghandili, Stefan Schmiedel, Katja Christina Weisel, Carsten Bokemeyer, Walter Fiedler · 2022 · Cancers
51. Japanese rapid/living recommendations on drug management for COVID ‐19: updated guidelines (July 2022)
    Kazuma Yamakawa, Ryo Yamamoto, Takero Terayama, Hideki Hashimoto, Tadashi Ishihara, Go Ishimaru, Haruki Imura, Hiromu Okano, Chihiro Narita, Takuya Mayumi et al. · 2022 · Acute Medicine & Surgery
52. Nirmatrelvir–Ritonavir (Paxlovid) for Mild Coronavirus Disease 2019 (COVID-19) in Pregnancy and Lactation
    Christine Y. Lin, Arianna G. Cassidy, Lin Li, Mary K. Prahl, Yarden Golan, Stephanie L. Gaw · 2023 · Obstetrics and Gynecology
53. Acute kidney injury in COVID-19 patients receiving remdesivir: A systematic review and meta-analysis of randomized clinical trials
    Golnaz Shams, Asma Kazemi, Khatereh Jafarian, Mohammad Hossein Morowvat, Payam Peymani, Iman Karimzadeh · 2023 · Clinics
54. Efficacy of combination therapy of fluvoxamine and favipiravir vs favipiravir monotherapy to prevent severe COVID-19 among mild to moderate COVID-19 patients: Open-label randomized controlled trial (EFFaCo study)
    Taweegrit Siripongboonsitti, Teerapat Ungtrakul, Kriangkrai Tawinprai, Tararin Nimmol, Mullika Buttakosa, Gaidganok Sornsamdang, Tanadul Jarrusrojwuttikul, Phumin Silapant, Nithi Mahanonda · 2023 · International Journal of Infectious Diseases
55. Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Intravenous Infusions of PF-07304814 (Lufotrelvir) in Participants Hospitalized With COVID-19
    Philip Robinson, Sima S. Toussi, Sudeepta Aggarwal, Arthur J. Bergman, Tong Zhu, Frances Hackman, Jean G. Sathish, Lawrence W. Updyke, Peter T. Loudon, Ganesh Krishna et al. · 2023 · Open Forum Infectious Diseases
56. Real-life comparison of mortality in patients with SARS-CoV-2 infection at risk for clinical progression treated with molnupiravir or nirmatrelvir plus ritonavir during the Omicron era in Italy: a nationwide, cohort study
    Carlo Torti, Pier Paolo Olimpieri, Paolo Bonfanti, Carlo Tascini, Simone Celant, Danilo Tacconi, Emanuele Nicastri, Evelina Tacconelli, Bruno Santi Cacopardo, Alessandro Perrella et al. · 2023 · The Lancet Regional Health - Europe
57. Care for adults with COVID ‐19: living guidelines from the National COVID ‐19 Clinical Evidence Taskforce
    Heath White, Steve J McDonald, Bridget E. Barber, Joshua Saul Davis, Lucy D. Burr, Priya Nair, Sutapa Mukherjee, Britta Tendal, Julian Elliott, Steven A. McGloughlin et al. · 2022 · The Medical Journal of Australia
58. Transcriptomics and RNA-Based Therapeutics as Potential Approaches to Manage SARS-CoV-2 Infection
    Cristian Arriaga-Canon, Laura Contreras‐Espinosa, Rosa Rebollar‐Vega, Rogelio Montiel-Manríquez, Alberto Cedro‐Tanda, José Antonio García-Gordillo, Rosa María Álvarez-Gómez, Francisco Javier Jiménez-Trejo, Clementina Castro Hernández, Luis A. Herrera · 2022 · International Journal of Molecular Sciences
59. Developmental safety of nirmatrelvir in zebrafish (Danio rerio) embryos
    Daniela Zizioli, Sara Ferretti, Luca Mignani, Francesco Castelli, Giorgio Tiecco, Isabella Zanella, Eugenia Quirós-Roldán · 2022 · Birth Defects Research
60. Impact of anti‐SARS‐CoV‐2 monoclonal antibodies in the management of patients with lymphoma and COVID19: A retrospective study
    Giovanni Manfredi Assanto, Alice Di Rocco, Francesco Malfona, Marcello Capriata, Ilaria Del Giudice, Luigi Petrucci, Paola Girardi, Gianna Maria D’Elia, Maurizio Martelli, Giuseppe Gentile et al. · 2022 · Hematological Oncology
61. “Saving lives with nirmatrelvir/ritonavir one transplant patient at a time”
    Katherine A. Belden, Sarah Yeager, Jamie Schulte, Maria Paula Martinez Cantarin, Sean Moss, Tricia L. Royer, Dagan Coppock · 2023 · Transplant Infectious Disease
62. Luteolin Isolated from Juncus acutus L., a Potential Remedy for Human Coronavirus 229E
    Asma Hakem, Lowiese M. B. Desmarets, Ramla Sahli, Rawen Ben Malek, Charline Camuzet, Nathan François, Gabriel Lefèvre, Jennifer Samaillie, Sophie Moureu, Sevser Şahpaz et al. · 2023 · Molecules
63. Antiviral effect and safety of nafamostat mesilate in patients with mild early-onset COVID-19: An exploratory multicentre randomized controlled clinical trial
    Shu Okugawa, Mahoko Ikeda, Kosuke Kashiwabara, Takashi Moritoyo, Takao Kohsaka, Toshio Shimizu, Hideharu Hagiya, Kou Hasegawa, Fumio Otsuka, Ayumi Miwa et al. · 2023 · International Journal of Antimicrobial Agents
64. To PCR or not? The impact of shifting policy from PCR to rapid antigen tests to diagnose COVID-19 during the omicron epidemic: a nationwide surveillance study
    Hsin Chi, Nan‐Chang Chiu, Chung-Chu Chen, Shun‐Long Weng, Chi-Hone Lien, Chao‐Hsu Lin, Yao-Feng Hu, Wei‐Te Lei, Yu‐Lin Tai, Liang-Yen Lin et al. · 2023 · Frontiers in Public Health
65. The importance of good practices and false hits for QSAR-driven virtual screening real application: a SARS-CoV-2 main protease (Mpro) case study
    Mateus Sá Magalhães Serafim, Simone Queiroz Pantaleão, Elany Barbosa da Silva, James Hobson McKerrow, Anthony John O’Donoghue, Bruno Eduardo Fernandes Mota, Káthia M. Honório, Vinícius Gonçalves Maltarollo · 2023 · Frontiers in Drug Discovery
66. Nirmatrelvir and ritonavir combination: an antiviral therapy for COVID-19
    Gangireddy Navitha Reddy, Akanksha Jogvanshi, Sana Naikwadi, Rajesh Sonti · 2023 · Expert Review of Anti-infective Therapy
67. Real-world nirmatrelvir-ritonavir outpatient treatment in reducing hospitalization for high-risk patients with COVID-19 during Omicron BA.4, BA.5 and XBB subvariants dominance in Malaysia: A retrospective cohort study
    Ee Vien Low, Mohan Dass Pathmanathan, Suresh Kumar Chidambaram, Wee Ric Kim, Wei Jia Lee, Zhi Wei Teh, Maheshwara Rao Appannan, Shahanizan Mohd Zin, Faizah Muhamad Zin, Samha Bashirah Mohamed Amin et al. · 2023 · International Journal of Infectious Diseases
68. Omicron related COVID-19 prevention and treatment measures for patients with hematological malignancy and strategies for modifying hematologic treatment regimes
    Wenjing Guo, Yizhou Zheng, Sizhou Feng · 2023 · Frontiers in Cellular and Infection Microbiology
69. Nirmatrelvir/Ritonavir Utilization for the Treatment of Non-hospitalized Adults with COVID-19 in the National Veterans Affairs (VA) Healthcare System
    Haley J. Appaneal, Kerry L. LaPlante, Vrishali Lopes, Catherine Martin, Laura Puzniak, Timothy Lee Wiemken, Evan J Zasowski, John M. McLaughlin, Aisling R. Caffrey · 2024 · Infectious Diseases and Therapy
70. Guidance for prevention and management of COVID-19 in children and adolescents: A consensus statement from the Pediatric Infectious Diseases Society Pediatric COVID-19 Therapies Taskforce
    Zachary Willis, Carlos R. Oliveira, Mark J. Abzug, Brenda I. Anosike, Monica I. Ardura, Laura L. Bio, Juri Boguniewicz, Kathleen Chiotos, Kevin J. Downes, Steven P Grapentine et al. · 2023 · Journal of the Pediatric Infectious Diseases Society
71. K-Means Clustering Identifies Diverse Clinical Phenotypes in COVID-19 Patients: Implications for Mortality Risks and Remdesivir Impact
    Carolina García‐Vidal, Christian Teijón‐Lumbreras, Tommaso Francesco Aiello, Mariana Chumbita, Rosario Menéndez, Aina Mateu-Subirà, Olivier Peyrony, Patricia Monzó, Carlos Lopera, Antonio Gallardo‐Pizarro et al. · 2024 · Infectious Diseases and Therapy
72. Ritonavir: 25 Years’ Experience of Concomitant Medication Management. A Narrative Review
    Romina Quercia, Giovanni Di Perri, C. Pein, Jennifer Bodie, Ravi Shankar Prasad Singh, Victoria Hendrick, Marta Boffito · 2024 · Infectious Diseases and Therapy
73. Treatment of chronic COVID ‐19 with convalescent/postvaccination plasma in patients with hematologic malignancies
    Maike Janssen, Albrecht Leo, Cornelia E. Wolf, Miriam Stenzinger, Marie Bartenschlager, Juliane Brandt, Sandra Sauer, Michael W. Schmitt, Peter Dreger, Richard F. Schlenk et al. · 2024 · International Journal of Cancer
74. Synthesis of α-Aminonitriles via Ammonium-Catalyzed Reactions of Aminoacetonitrile
    Xiangyuan Liu, Yu Deng, Tianran Deng, Yang Yu, Yuhong Gao, Xiang‐Lei Han, Cheng Cheng, Jisheng Luo, Li Deng · 2024 · Journal of the American Chemical Society
75. Development of small molecule non-covalent coronavirus 3CL protease inhibitors from DNA-encoded chemical library screening
    Hengrui Liu, Arie Zask, F. Forouhar, Sho Iketani, Alana D. N. Williams, Daniel R. Vaz, Dahlya Habashi, Karenna Choi, Samuel J. Resnick, Seo Jung Hong et al. · 2025 · Nature Communications
76. Dual Inhibitors of SARS-CoV-2 3CL Protease and Human Cathepsin L Containing Glutamine Isosteres Are Anti-CoV-2 Agents
    Vivek Kumar, Jiyun Zhu, Balachandra Chenna, Zoe A. Hoffpauir, Andrew Rademacher, Ashley M. Rogers, Chien-Te Kent Tseng, Aleksandra K. Drelich, Sharfa Farzandh, Audrey L. Lamb et al. · 2025 · Journal of the American Chemical Society
77. Oral antiviral treatment in patients with systemic rheumatic disease at risk for development of severe COVID-19: a case series
    G. Fragoulis, Christos Koutsianas, Kalliopi Fragiadaki, Ilias Mariolis, Stylianos Panopoulos, Christina Tsalapaki, Maria Belen Pappa, Theodoros Dimitroulas, Maria G. Tektonidou, Dimitrios Vassilopoulos et al. · 2022 · Annals of the Rheumatic Diseases
78. Comparative Pharmacokinetics of Tixagevimab/Cilgavimab ( AZD7442 ) Administered Intravenously Versus Intramuscularly in Symptomatic SARS‐CoV ‐2 Infection
    Rachel Bender Ignacio, David Alain Wohl, Rosalin Arends, Venkatesh Pilla Reddy, Ying Mu, Arzhang Cyrus Javan, Michael D. Hughes, Joseph J. Eron, Judith S. Currier, Davey M. Smith et al. · 2022 · Clinical Pharmacology & Therapeutics
79. Nirmatrelvir–remdesivir association for non-hospitalized adults with COVID-19, point of view
    Francesco Ferrara, Andrea Zovi, Ugo Trama, Antonio Vitiello · 2022 · Inflammopharmacology
80. Recent Developments in the Understanding of Immunity, Pathogenesis and Management of COVID-19
    Aram Yegiazaryan, Arbi Abnousian, Logan J. Alexander, Ali Badaoui, Brandon Flaig, Nisar Sheren, Armin Aghazarian, Dijla Alsaigh, Arman Amin, Akaash Mundra et al. · 2022 · International Journal of Molecular Sciences
81. Use of Human Lung Tissue Models for Screening of Drugs against SARS-CoV-2 Infection
    Alexander J. McAuley, Petrus Jansen van Vuren, Muzaffar-Ur-Rehman Mohammed, Faheem Faheem, Sarah Goldie, Shane Riddell, Nathan Gödde, Ian K. Styles, Matthew P. Bruce, Simran Chahal et al. · 2022 · Viruses
82. The unmet need for COVID-19 treatment in immunocompromised patients
    Alessandra D’Abramo, Serena Vita, Emanuele Nicastri · 2022 · BMC Infectious Diseases
83. AGIHO guideline on evidence-based management of COVID-19 in cancer patients: 2022 update on vaccination, pharmacological prophylaxis and therapy in light of the omicron variants
    Nicola Giesen, Elena Busch, Enrico Schalk, Gernot Beutel, Maria Madeleine Rüthrich, Marcus Hentrich, Bernd Hertenstein, Hans Hellmuth Hirsch, Meinolf Karthaus, Yascha Khodamoradi et al. · 2022 · European Journal of Cancer
84. Factors associated with viral rebound among COVID-19 patients receiving oral antivirals
    Pao‐Yu Chen, Jann‐Tay Wang, Sui‐Yuan Chang, Chien‐Ching Hung, Chi‐Tai Fang, Aristine Cheng, Wang-Da Liu, Yu‐Shan Huang, Kuan‐Yin Lin, Hsin‐Yun Sun et al. · 2023 · Journal of the Formosan Medical Association
85. Use of Oral Antivirals Ritonavir-Nirmatrelvir and Molnupiravir in Patients with Multiple Myeloma Is Associated with Low Rates of Severe COVID-19: A Single-Center, Prospective Study
    Vasiliki Spiliopoulou, Ioannis Ntanasis‐Stathopoulos, Panagiotis Malandrakis, Maria Gavriatopoulou, Foteini Theodorakakou, Despina Fotiou, Magdalini Migkou, Μαρία Ρούσσου, Evangelos Eleutherakis‐Papaiakovou, Efstathios Kastritis et al. · 2023 · Viruses
86. FDA approved drugs with antiviral activity against SARS-CoV-2: From structure-based repurposing to host-specific mechanisms
    Mahmoud S. Ahmed, Ayman Farag, Ian N. Boys, Ping Wang, Ivan Menendez-Montes, Ngoc Uyen Nhi Nguyen, Jennifer L. Eitson, Maikke B. Ohlson, Wenchun Fan, Matthew B. McDougal et al. · 2023 · Biomedicine & Pharmacotherapy
87. Efficacy of Molnupiravir for the Treatment of Mild or Moderate COVID-19 in Adults: A Meta-Analysis
    Karima Benaicha, Raja Ram Khenhrani, Maha Veer, Sapna Devi, Usman Shahbaz, Qais M Salah, Mostafa Hammad, Sujith Kumar Palleti · 2023 · Cureus
88. Effects of itraconazole and carbamazepine on the pharmacokinetics of nirmatrelvir/ritonavir in healthy adults
    Donna S. Cox, Lien Van Eyck, Sylvester Pawlak, Bruce Beckerman, Carlos Linn, Katherine Ginman, Youliny Thay, Robert R. LaBadie, Haihong Shi, Bharat D. Damle · 2023 · British Journal of Clinical Pharmacology
89. Computational and Enzymatic Studies of Sartans in SARS-CoV-2 Spike RBD-ACE2 Binding: The Role of Tetrazole and Perspectives as Antihypertensive and COVID-19 Therapeutics
    Konstantinos Kelaidonis, Irene Ligielli, Spiros Letsios, Veroniki P. Vidali, Thomas Mavromoustakos, Niki Vassilaki, Graham J. Moore, Weronika Hoffmann, Katarzyna E. Wegrzyn, Harry F. Ridgway et al. · 2023 · International Journal of Molecular Sciences
90. Contribution of traditional Japanese Kampo medicines, kakkonto with shosaikotokakikyosekko, in treating patients with mild-to-moderate coronavirus disease 2019: Further analysis of a multicenter, randomized controlled trial
    Shin Takayama, Takao Namiki, Ryutaro Arita, Rie Ono, Akiko Kikuchi, Minoru Ohsawa, Natsumi Saito, Satoko Suzuki, Hajime Nakae, Seiichi Kobayashi et al. · 2023 · Journal of Infection and Chemotherapy
91. COVID‐19: An Overview of SARS‐CoV‐2 Variants—The Current Vaccines and Drug Development
    Narjess Bostanghadiri, Pardis Ziaeefar, Morvarid Golrokh Mofrad, Parsa Yousefzadeh, Ali Hashemi, Davood Darban‐Sarokhalil · 2023 · BioMed Research International
92. Nirmatrelvir/ritonavir for the treatment of immunocompromised adult patients with early‐stage symptomatic COVID‐19: A real‐life experience
    José María Caso, Mario Fernández‐Ruiz, Francisco López‐Medrano, José Manuel Caro Teller, Manuel Lizasoaín, Rafael San Juan, Marina Fayos, Isabel Rodríguez‐Góncer, José Tiago Silva, José María Aguado · 2023 · Journal of Medical Virology
93. Safety and efficacy of inhaled interferon-β1a (SNG001) in adults with mild-to-moderate COVID-19: a randomized, controlled, phase II trial
    Prasanna Jagannathan, Kara W Chew, Mark J Giganti, Michael D. Hughes, Carlee Moser, Mark Main, Phillip Monk, Arzhang Cyrus Javan, Jonathan Z. Li, Courtney Vail Fletcher et al. · 2023 · EClinicalMedicine
94. Oral Molnupiravir and Nirmatrelvir/Ritonavir for the Treatment of COVID-19: A Literature Review with a Focus on Real-World Evidence
    Ioannis Karniadakis, Nikolaos Mazonakis, Constantinos Tsioutis, Michail Papadakis, Ioulia Markaki, Nikolaos A. Spernovasilis · 2023 · Infectious Disease Reports
95. Estimating the potential impact and diagnostic requirements for SARS-CoV-2 test-and-treat programs
    Alvin X. Han, Emma Hannay, Sergio Carmona, Bill Rodriguez, Brooke E Nichols, Colin A. Russell · 2023 · Nature Communications
96. Treating Acute Covid-19 — Final Chapters Still Unwritten
    Rajesh Tim Gandhi, Martin Hirsch · 2024 · New England Journal of Medicine
97. Independent FDA Analyses of Nirmatrelvir/Ritonavir Resistance in the Phase 2/3 Trials EPIC-HR and EPIC-SR
    Jonathan M. O. Rawson, Eric Donaldson, Julian J. O’Rear, Patrick R. Harrington · 2024 · Clinical Infectious Diseases
98. Antiviral Activity of N1,N3-Disubstituted Uracil Derivatives against SARS-CoV-2 Variants of Concern
    Andrei E. Siniavin, Mikhail Sergeevich Novikov, Vladimir А. Gushchin, Alexander A. Terechov, Igor A. Ivanov, Maria P. Paramonova, E. S. Gureeva, Leonid I. Russu, Nadezhda A. Kuznetsova, Elena V. Shidlovskaya et al. · 2022 · International Journal of Molecular Sciences
99. HIV Glasgow, 23–26 October 2022, Glasgow, UK / Virtual
    E Akalin, Mehmet Serhat Birengel, Taner Yıldırmak, Tuna Demırdal, Ömer Haluk Eraksoy, İlkay Karaoğlan, İnan Asuman, Aydin Deveci, Hülya Özkan Özdemir, Ayşe Deniz Gökengin et al. · 2022 · Journal of the International AIDS Society
100. Exocyst complex component 2 is a potential host factor for SARS-CoV-2 infection
     Renxing Yi, Rina Hashimoto, Ayaka Sakamoto, Yasufumi Matsumura, Miki Nagao, Kazutoshi Takahashi, Kazuo Takayama · 2022 · iScience